Sunshine Heart (CHFS) Given Coverage Optimism Rating of 0.02

News coverage about Sunshine Heart (NASDAQ:CHFS) has trended somewhat positive this week, according to Accern. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Sunshine Heart earned a news sentiment score of 0.02 on Accern’s scale. Accern also assigned media stories about the company an impact score of 46.0591308853816 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the news articles that may have impacted Accern Sentiment’s scoring:

Shares of Sunshine Heart (CHFS) traded up $0.12 during midday trading on Tuesday, reaching $3.17. The company’s stock had a trading volume of 138,700 shares, compared to its average volume of 563,159. The stock has a market capitalization of $5.70, a price-to-earnings ratio of -0.02 and a beta of 2.34. Sunshine Heart has a 52 week low of $2.87 and a 52 week high of $101.80.

Several research firms have recently commented on CHFS. Zacks Investment Research lowered shares of Sunshine Heart from a “buy” rating to a “hold” rating in a research report on Friday, January 5th. ValuEngine raised shares of Sunshine Heart from a “strong sell” rating to a “sell” rating in a research report on Tuesday, October 31st.

COPYRIGHT VIOLATION WARNING: “Sunshine Heart (CHFS) Given Coverage Optimism Rating of 0.02” was posted by BBNS and is the sole property of of BBNS. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this piece of content can be read at https://baseballnewssource.com/markets/sunshine-heart-chfs-given-coverage-optimism-rating-of-0-02/1893512.html.

About Sunshine Heart

CHF Solutions, Inc, an early-stage medical device company, develops cardiac and coronary disease products primarily in the United States. It focused on commercializing the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.

Insider Buying and Selling by Quarter for Sunshine Heart (NASDAQ:CHFS)

Receive News & Ratings for Sunshine Heart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Heart and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Red Sox: J.D. Martinez Continues His Physical at Spring Training Facility
Red Sox: J.D. Martinez Continues His Physical at Spring Training Facility
Three-Way Trade Sends Souza to Diamondbacks and Drury to Yankees
Three-Way Trade Sends Souza to Diamondbacks and Drury to Yankees
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Cubs Sign Free Agent Yu Darvish
Cubs Sign Free Agent Yu Darvish


Leave a Reply

 
© 2006-2018 BBNS.